Immune System Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
Examining the genetic links between clusters of immune-mediated diseases and psychiatric disorders.
Molecular Insight into the Role of Vitamin D in Immune-Mediated Inflammatory Diseases.
piRNA associates with immune diseases.
PD-L1 Blockade Improves Survival in Sepsis by Reversing Monocyte Dysfunction and Immune Disorder.
Antibody Cross-Reactivity in Auto-Immune Diseases.
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q2 2027.
- Q2 2027Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- Q4 2027A Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A Nephropathy
- Q4 2031Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Clinical MilestonesViewHide
- 2026-07-02Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell LymphomaResults expected Q2 2027
- 2026-06-30Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesResults expected Q4 2031
- 2026-06-03A Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A NephropathyResults expected Q4 2027
- 2025-12-16Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's LymphomaPrimary completion
- 2025-11-01A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut AllergyPrimary completion
- 2026-12-01A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawn
- 2026-11-01A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune ThrombocytopeniaWithdrawn
- 2026-12-01ClinicalA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawn
- 2026-11-01ClinicalA Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune ThrombocytopeniaWithdrawn
- 2026-07-02ClinicalPhase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell LymphomaResults expected Q2 2027
- 2026-06-30ClinicalPilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesResults expected Q4 2031
- 2026-06-03ClinicalA Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A NephropathyResults expected Q4 2027
- 2026-03-17ClinicalPhase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationResults posted
- 2025-12-16ClinicalPhase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's LymphomaPrimary completion
- 2025-11-01ClinicalA Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut AllergyPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Immune System Diseases9
- Autoimmune Diseases2
- Brain Neoplasms1
- Carcinoma, Renal Cell1
- Databases, Pharmaceutical1
- Disease Susceptibility1
- Gastrointestinal Microbiome1
- Gene Expression1
Leading journals6
- International journal of molecular sciences3
- Frontiers in immunology2
- Journal for immunotherapy of cancer2
- Bone marrow transplantation1
- Cell communication and signaling : CCS1
- Environmental health and preventive medicine1
Leading researchers8
- Franco JL2
- Puel A2
- Su HC2
- Abel L1
- Abolhassani H1
- Abushahin L1
- Adeniran A1
- Aiuti A1
Affiliations (unnormalised)6
- Brigham and Women's Hospital4
- Harvard Medical School2
- IRCCS San Raffaele Scientific Institute2
- Laboratory of Human Genetics of Infectious Diseases2
- Sorbonne University2
- Allen Institute for Immunology1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Immune system diseases are disorders caused by abnormal or absent immunologic mechanisms. They can involve humoral immunity, cell-mediated immunity, or both, and the literature frames them as a broad group of immune-mediated conditions rather than a single disease entity.
The grounding supports immune dysregulation as the central cause, including abnormal or absent humoral and/or cell-mediated immune mechanisms. It also links immune-mediated disease to autoimmunity and to dysbiosis-related immune disturbance, but does not support a single unified aetiology for the category as a whole.
The biological basis is failure of normal immune function, with downstream abnormalities in cytokine signaling, T-cell subset balance, and costimulatory pathways. The supplied literature also points to immune dysfunction involving Th17 cells, regulatory and helper T-cell subsets, and altered interactions between immune cells and tissue targets.
The grounding does not support specific risk factors for immune system diseases as a category. It does indicate that gut microbiota dysbiosis, diet, and antibiotics can contribute to immune dysregulation in some immune-mediated contexts, but not as universal risk factors.
The supplied material supports treatment at the level of broad modalities such as drug therapy and therapy, but does not define a single standard regimen for this category. It also references immunotherapy-related approaches in the broader immune-disease literature, including immune checkpoint inhibition and T-cell engaging therapies, but these are not presented as standard care for immune system diseases overall.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.